利用Wnt靶基因表达差异构建结直肠癌分层分子生物标志物
该研究通过多组学分析发现,结直肠癌中配体依赖型(LD)与配体非依赖型(LI)Wnt通路突变互斥,LD肿瘤存在Wnt负调控基因(如AXIN2、NKD1)的表观遗传沉默,AXIN2 mRNA表达可作为区分LD/LI肿瘤的分子生物标志物(AUC>0.93),LD患者可能对Wnt配体抑制敏感。
要点
- Wnt通路突变在结直肠癌中互斥,可分为配体非依赖型(LI)和配体依赖型(LD)。
- LD肿瘤中Wnt负调控基因(AXIN2、NKD1)存在高甲基化沉默,AXIN2 mRNA表达可区分LD/LI(AUC>0.93)。
- LD肿瘤患者保留对Wnt配体抑制的敏感性,可在诊断时分层进入Porcupine抑制剂临床试验。
核心结论
- LD肿瘤中选择性有利于Wnt负反馈环的表观遗传抑制,AXIN2表达差异可作为区分LD/LI的分子生物标志物。
- 区分LD/LI肿瘤类型很重要,LD患者保留对Wnt配体抑制的敏感性,可分层进入Porcupine抑制剂临床试验。
研究设计与样本
- 对发现队列(n=684)和验证队列(n=578)的结直肠肿瘤进行统一多组学分析,数据来自公开数据库和Stratification in Colorectal Cancer Consortium。
- 利用突变数据建立分子基准,将病变分为LI/LD肿瘤亚组,比较转录、甲基化、形态和临床特征。
主要发现
- Wnt破坏性突变是互斥的。
- 在部分间质丰富的肿瘤中,间质促结缔组织增生上调RSPO可能补偿上皮突变的缺失。
- 关键Wnt负调控基因在LD/LI肿瘤间差异表达,部分基因(AXIN2、NKD1)的靶向高甲基化甚至发生在CIMP阴性LD癌症中。
- AXIN2 mRNA表达作为区分LD/LI肿瘤的生物标志物,曲线下面积(AUC)>0.93。
关键数值与推荐
- AXIN2 mRNA表达区分LD/LI肿瘤的AUC>0.93。
临床怎么用
- 可利用AXIN2 mRNA表达在诊断时区分LD/LI肿瘤,将LD患者分层进入Porcupine抑制剂临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Pathological Wnt pathway activation is a conserved hallmark of colorectal cancer. Wnt-activating mutations can be divided into: i) ligand-independent (LI) alterations in intracellular signal transduction proteins (Adenomatous polyposis coli, β-catenin), causing constitutive pathway activation and ii) ligand-dependent (LD) mutations affecting the synergistic R-Spondin axis (RNF43, RSPO-fusions) acting through amplification of endogenous Wnt signal transmembrane transduction. Our aim was to exploit differential Wnt target gene expression to generate a mutation-agnostic biomarker for LD tumours. DESIGN: We undertook harmonised multi-omic analysis of discovery (n=684) and validation cohorts (n=578) of colorectal tumours collated from publicly available data and the Stratification in Colorectal Cancer Consortium. We used mutation data to establish molecular ground truth and subdivide lesions into LI/LD tumour subsets. We contrasted transcriptional, methylation, morphological and clinical characteristics between groups. RESULTS: Wnt disrupting mutations were mutually exclusive. Desmoplastic stromal upregulation of RSPO may compensate for absence of epithelial mutation in a subset of stromal-rich tumours. Key Wnt negative regulator genes were differentially expressed between LD/LI tumours, with targeted hypermethylation of some genes (AXIN2, NKD1) occurring even in CIMP-negative LD cancers. AXIN2 mRNA expression was used as a discriminatory molecular biomarker to distinguish LD/LI tumours (area under the curve >0.93). CONCLUSIONS: Epigenetic suppression of appropriate Wnt negative feedback loops is selectively advantageous in LD tumours and differential AXIN2 expression in LD/LI lesions can be exploited as a molecular biomarker. Distinguishing between LD/LI tumour types is important; patients with LD tumours retain sensitivity to Wnt ligand inhibition and may be stratified at diagnosis to clinical trials of Porcupine inhibitors.
引用
- Kleeman SO, Koelzer VH, Jones HJ, et al. Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification. Gut. 2019. PMID: 31563876. doi:10.1136/gutjnl-2019-319126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。